Pharmaceutical products: 70%
Consumer goods: 20%
Veterinary products: 10%

TOP 3 markets:
India: 60%
Southeast Asia: 20%
Africa: 10%

Mankind Pharma Limited generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 70% of total revenue. In addition to the pharmaceutical industry, the company is also active in the consumer goods and veterinary products sectors.

The Indian market is the most significant for Mankind Pharma, representing 60% of total revenue. Southeast Asia and Africa follow as important markets with shares of 20% and 10%, respectively. These markets continue to offer potential for future growth due to their growing populations and increasing healthcare expenditures.

Production Facilities: India

Mankind Pharma Limited mainly produces its products in India. The company has several production facilities across the country specializing in the manufacturing of pharmaceutical products, health products, and other related items.

These production facilities are strategically located in various regions of India to efficiently cater to domestic demand and facilitate exports to international markets. Mankind Pharma places great emphasis on adhering to international quality standards in its production processes.

Revenue Growth: Estimated 10-12% annually (2025-2027)

Focus on Research and Development: Mankind Pharma is increasing its investment in research and development to bring innovative products to the market. This includes both expanding the existing portfolio and developing new medications.

Market Expansion: The company plans to expand its presence in international markets, especially in emerging countries, to benefit from the increasing demand for health products.

Digitalization and Technology: Mankind Pharma is focusing on digitizing processes and utilizing modern technologies to achieve efficiency improvements and enhance customer experience.

These strategic initiatives are intended to secure the company's growth in the coming years and strengthen its competitiveness on a global scale.

Main raw materials: Active Pharmaceutical Ingredients (APIs), Packaging materials
Countries of origin: China, Germany, USA, Italy

Mankind Pharma Limited mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their medications. These are primarily sourced from China, as the country is one of the largest producers of APIs worldwide.

Additionally, the company imports packaging materials necessary for the safe and effective distribution of their products. These materials often come from countries like Germany and the USA, known for their high-quality packaging technologies.

Italy is also an important partner, especially for specialized pharmaceutical components and technologies. Diversifying the countries of origin helps Mankind Pharma ensure supply security and benefit from various technological advancements.

Market share in India: approximately 4.3% (2023)
Revenue growth: 16.5% (2023)
EBITDA margin: 24.1% (2023)

Mankind Pharma Limited has established itself as one of the leading players in the Indian pharmaceutical market. With a market share of around 4.3%, the company is among the top pharmaceutical companies in India. The revenue growth of 16.5% in 2023 demonstrates the company's ability to expand in a competitive environment.

A key competitive advantage of Mankind Pharma lies in its strong presence in the generics and over-the-counter medication segment, which are in high demand in India. The EBITDA margin of 24.1% underscores the operational efficiency and the company's ability to control costs while growing profitably.

Additionally, Mankind Pharma benefits from a wide range of products and a well-established distribution network that enables rapid market penetration. Continuous investment in research and development also ensures the company's innovation capabilities and strengthens its long-term competitive position.

Institutional Investor Share: 23% (2025, estimated) Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Mankind Pharma Limited is estimated to be around 23%. This indicates that a significant portion of the shares are held by institutional investors, suggesting confidence in the company's long-term performance.

In 2025, there were no significant insider buys or sells, indicating that the management and other insiders are currently not making significant changes to their stake in the company. This could be interpreted as a sign of stability and confidence in the current corporate strategy.

Market share of Mankind Pharma Limited: 5.2% (2025, estimated)

Top competitors and their market shares:

1. Sun Pharmaceutical Industries Ltd.: 8.9%
2. Cipla Ltd.: 7.5%
3. Dr. Reddy's Laboratories Ltd.: 6.8%
4. Lupin Ltd.: 6.0%
5. Aurobindo Pharma Ltd.: 5.5%
6. Mankind Pharma Limited: 5.2%
7. Zydus Cadila: 4.8%
8. Glenmark Pharmaceuticals Ltd.: 4.3%
9. Torrent Pharmaceuticals Ltd.: 4.0%
10. Biocon Ltd.: 3.7%

Mankind Pharma's Economic Moat:

Mankind Pharma has built a certain economic moat through its strong brand presence and a wide product portfolio. The company is known for its affordable medications and a strong distribution network in rural and urban areas of India. These factors provide a competitive advantage, especially in price-sensitive markets.

However, compared to larger competitors like Sun Pharmaceutical and Cipla, which have more extensive international networks and research capabilities, Mankind Pharma's economic moat is less pronounced. These companies often have a technological and innovative advantage that helps them bring new patented medications to market faster.

In summary, while Mankind Pharma has a solid market share and some competitive advantages, its economic moat is less deep compared to industry leaders. Nevertheless, the ability to offer cost-effective products and maintain a strong local presence remains a significant advantage.

Revenue Growth: 18% (2024)
EBITDA Margin: 22% (2024)
R&D Expenses: 5% of revenue (2024)

Mankind Pharma Limited shows a solid revenue growth of 18% in 2024, indicating strong demand for its products and effective market expansion. The EBITDA margin of 22% demonstrates that the company operates efficiently and is able to control its costs well while remaining profitable.

The investment in research and development, accounting for 5% of revenue, suggests that Mankind Pharma is striving to remain competitive through innovations and new products. This could lead to a stronger market position and further growth opportunities in the long term.

Overall, these indicators suggest that Mankind Pharma is pursuing a stable and growth-oriented business strategy, making the stock a potentially good investment, especially for investors interested in long-term growth.

Dividend Yield: 1.5% (estimated for 2025)

Mankind Pharma Limited has started distributing dividends to its shareholders regularly in recent years. The company's dividend policy shows a tendency towards stability, with payouts remaining constant in recent years.

The reliability of dividend payments is supported by the company's solid financial performance. Mankind Pharma has seen steady revenue and profit growth in recent years, strengthening its ability to pay dividends. Analysts expect the company to continue this practice unless significant economic or industry-specific challenges arise.